elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Taxane
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Taxane
RIS
0.001
(Research Intensity Score)
Papers
142
Top papers
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2024 · 277 citations
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
2023 · 281 citations
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
2022 · 301 citations
Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides
2024 · 75 citations
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
2025 · 33 citations
Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591
2023 · 70 citations
Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy
2025 · 32 citations
LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
2023 · 69 citations
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
2023 · 98 citations
Newest papers
A survey method using three indicators (total, regimen, and each line contribution periods) to understand the actual treatment status for patients with recurrent ovarian cancer in real-world clinical practice
2026
Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2026
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
2026
Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study
2026
PARP inhibitors plus ARSI in first-line mCRPC—a treatment for all patients?
2026
Podium Session 3: Oncology - Prostate
2026
Association of SPOP mutation with survival outcomes following 177 Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC).
2026
Circulating tumour DNA in mCRPC: bridging tumour biology and real-time treatment monitoring
2026
PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencing
2026
Browse all papers →
Taxane's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Taxane's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link